Adaptin Bio, Inc. (APTN) — SEC Filings
Adaptin Bio, Inc. (APTN) — 15 SEC filings. Latest: 8-K (Dec 23, 2025). Includes 6 10-Q, 4 8-K, 2 S-1/A.
View Adaptin Bio, Inc. on SEC EDGAR
Overview
Adaptin Bio, Inc. (APTN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 23, 2025: On December 22, 2025, ADAPTIN BIO, INC. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The company, formerly known as Unite Acquisition 1 Corp., is incorporated in Delaware and based in Charlotte, North Carolina.
Sentiment Summary
Across 15 filings, the sentiment breakdown is: 1 bearish, 13 neutral, 1 mixed. The dominant filing sentiment for Adaptin Bio, Inc. is neutral.
Filing Type Overview
Adaptin Bio, Inc. (APTN) has filed 4 8-K, 6 10-Q, 2 S-1/A, 1 S-1, 2 10-K with the SEC between Apr 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (15)
Risk Profile
Risk Assessment: Of APTN's 14 recent filings, 2 were flagged as high-risk, 6 as medium-risk, and 6 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | $ -3,799,551 |
| EPS | $ -0.20 |
| Cash Position | $ 579,089 |
| Total Assets | $ 979,474 |
| Total Debt | $ 1,860,552 |
Key Executives
- Michael J. Roberts, PhD
- Donald R. Reynolds, Esq.
- S. Halle Vakani, Esq.
- Jonathan A. Greene, Esq.
Industry Context
Adaptin Bio, Inc. operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space typically face long development cycles, significant R&D costs, and regulatory hurdles. Success often hinges on groundbreaking scientific discoveries, effective clinical trials, and securing substantial funding for research, development, and commercialization.
Top Tags
10-Q (4) · quarterly-report (4) · Biotechnology (3) · Emerging Growth Company (3) · SEC Filing (3) · equity-sale (2) · S-1/A Filing (2) · sec-filing (2) · 10-K (2) · Unite Acquisition 1 Corp. (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 000-56583 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 88-1566415 | Company's tax identification number. |
| Net Loss (Q3 2025) | $1.68M | Increased from $1.11M in Q3 2024, indicating worsening financial performance. |
| Net Loss (YTD Q3 2025) | $3.80M | Increased from $2.27M in YTD Q3 2024, showing a significant rise in losses. |
| Accumulated Deficit | $7.92M | As of September 30, 2025, highlighting substantial historical losses and financial instability. |
| Cash and Cash Equivalents | $579K | As of September 30, 2025, up from $34K at Dec 31, 2024, but still insufficient for long-term operations. |
| Net Cash from Financing | $4.62M | For nine months ended September 30, 2025, primarily from a private placement, crucial for current liquidity. |
| Total Operating Expenses (YTD Q3 2025) | $4.05M | Increased from $2.06M in YTD Q3 2024, driven by higher G&A post-merger. |
| Common Shares Outstanding | 8,455,829 | As of November 13, 2025, reflecting dilution from the merger and private placement. |
| Basic Net Loss Per Share (Q3 2025) | $0.20 | Compared to $0.34 in Q3 2024, showing a lower per-share loss despite higher net loss due to increased share count. |
| Commission File Number | 001-56583 | Identifies the company's filing with the SEC |
| EIN | 88-1566415 | Employer Identification Number for tax purposes |
| Central Index Key (CIK) | 0001938571 | Unique identifier for ADAPTIN BIO, INC. with the SEC. |
| Standard Industrial Classification (SIC) Code | 2836 | Indicates the company operates in the 'Biological Products (No Diagnostic Substances)' industry. |
| IRS Employer Identification Number (EIN) | 88-1566415 | Tax identification number for ADAPTIN BIO, INC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Adaptin Bio, Inc. (APTN)?
Adaptin Bio, Inc. has 15 recent SEC filings from Apr 2024 to Dec 2025, including 6 10-Q, 4 8-K, 2 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of APTN filings?
Across 15 filings, the sentiment breakdown is: 1 bearish, 13 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Adaptin Bio, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Adaptin Bio, Inc. (APTN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Adaptin Bio, Inc.?
Key financial highlights from Adaptin Bio, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for APTN?
The investment thesis for APTN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Adaptin Bio, Inc.?
Key executives identified across Adaptin Bio, Inc.'s filings include Michael J. Roberts, PhD, Donald R. Reynolds, Esq., S. Halle Vakani, Esq., Jonathan A. Greene, Esq..
What are the main risk factors for Adaptin Bio, Inc. stock?
Of APTN's 14 assessed filings, 2 were flagged high-risk, 6 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Adaptin Bio, Inc.?
Forward guidance and predictions for Adaptin Bio, Inc. are extracted from SEC filings as they are enriched.